Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia-Reference-Cited by-同舟云学术

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Published:2017-10-12 Issue:15 Volume:130 Page:1713-1721
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Anguille Sébastien¹²,Van de Velde Ann L.¹²,Smits Evelien L.²,Van Tendeloo Viggo F.²,Juliusson Gunnar³,Cools Nathalie²,Nijs Griet¹²,Stein Barbara¹²,Lion Eva²,Van Driessche Ann¹²,Vandenbosch Irma¹,Verlinden Anke¹²,Gadisseur Alain P.¹²,Schroyens Wilfried A.¹²,Muylle Ludo¹²,Vermeulen Katrien¹,Maes Marie-Berthe¹,Deiteren Kathleen¹,Malfait Ronald¹,Gostick Emma⁴,Lammens Martin¹,Couttenye Marie M.¹,Jorens Philippe¹,Goossens Herman¹²,Price David A.⁴,Ladell Kristin⁴,Oka Yoshihiro⁵,Fujiki Fumihiro⁶,Oji Yusuke⁷,Sugiyama Haruo⁶,Berneman Zwi N.¹²

Affiliation:

1. Antwerp University Hospital, Antwerp, Belgium;

2. Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;

3. Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden;

4. Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, United Kingdom; and

5. Department of Respiratory Medicine, Allergy & Rheumatic Diseases,

6. Department of Cancer Immunology, and

7. Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan

Abstract

Key Points WT1 mRNA-electroporated DCs can prevent or delay relapse in 43% of patients with AML in remission after chemotherapy. OS compares favorably with the new survival data from the Swedish Acute Leukemia Registry and correlates with molecular and WT1-specific CD8+ T-cell responses.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/15/1713/1402922/blood780155.pdf

Reference50 articles.

1. SEER Cancer Statistics Review, 1975-2012;Howlader

2. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012;Dinmohamed;Leukemia,2016

3. Relapsed acute myeloid leukemia: why is there no standard of care?;Ravandi;Best Pract Res Clin Haematol,2013

4. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers;Anguille;Hum Vaccin,2011

5. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence;van Besien;Hematology Am Soc Hematol Educ Program,2013

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines;Vaccines;2024-02-06

2. The role of dendritic cells in cancer immunity and therapeutic strategies;International Immunopharmacology;2024-02

3. Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective;Biomedicine & Pharmacotherapy;2024-02

4. Vaccines: a promising therapy for myelodysplastic syndrome;Journal of Hematology & Oncology;2024-01-08

5. Advances, opportunities and challenges in developing therapeutic cancer vaccines;Critical Reviews in Oncology/Hematology;2024-01